RPCEC00000260尚未招募1 期
Bioequivalence study of an extended release formulation of Diltiazem (120 mg) in healthy volunteers
Center for Pharmaceutical Research and Development, Havana, Cuba.0 个研究点目标入组 24 人开始时间: 2017年11月28日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled trial. Masking: Double Blind. Control group: Active. Assignment: Crossover. Purpose: Other
入排标准
- 年龄范围
- 18 years 至 50 years（—）
- 性别
- All
入选标准
- •1- Written informed consent.
- •2- Aged between 18-50 years.
- •3- Volunteers of both sexes.
- •4- Volunteers’ weight: +/- 15% of their ideal weight for height.
- •5- Failure to submit evidence of organic or psychiatric disease according to interrogation, physical examination and laboratory tests.
- •6- Not have evidence or history of diseases such as bronchial asthma, hypertension, bad-absorption syndrome, peptic ulcer or duodenal present, liver failure, kidney failure, severe allergic reactions, atopic dermatitis, cardiovascular disorders, diabetes mellitus.
- •7- Satisfactory physical examination.
- •8- Present vital signs values within the following reference ranges. Systolic blood pressure between 90 and 130 mm Hg and diastolic blood pressure between 60 and 80 mm Hg, heart rate between 60 to 100 beats per minute, respiratory rate between 12 to 20 breaths per minute.
- •9- Not having consumed alcohol, drinks containing xanthines (tea, coffee, and cola) and carbonated beverages three days before the start of each period and during it.
- •10- Smoking or non-smoking subjects. A record of cigars use will be made.
- •11- Laboratory results within the acceptance range. For some parameters such as blood counts with differential, urine, etc., a result found outside the reference range will be carefully evaluated by the clinical investigator.
- •12- Post-menopausal women (age 45 or older with at least two years of amenorrhea) or documented history of hysterectomy and / or oophorectomy double sex.
- •13- Female subject within childbearing age who use a (non-hormonal) contraceptive effective method at least 14 days before the first dose of product research and continued throughout the study. The decision to use effective contraception will be conducted by the principal investigator or clinical investigator responsible of medical care.
排除标准
- •1- Failure to comply with any of the inclusion criteria.
- •2- History of allergy, idiosyncratic or hypersensitivity to diltiazem or the components of the formulations under study.
- •3- Refer some viral disease in the last 7 days.
- •4- To be ingesting some medication 15 days (or for 5 half-lives) before the first dose of product research or nonprescribed or free drugs (OTC drugs) or herbal medicines / dietary supplements in a period seven days before the first dose of research products until the end of the study.
- •5- Total bilirubin values hihger than 1.5 times the upper limit of the reference range.
- •6- Serum creatinin values higher than 1.5 times the upper limit of the reference range.
- •7- Values of AST, ALT and GGT higher than 2 times the upper limit of the reference range.
- •8- Positive for hepatitis B and C virus, HIV or serology.
- •9- History of alcoholism in the past 6 months (not less consumption a quarter of a bottle of rum or one (1) bottle of wine or three (3) beers in a higher frequency of twice a week.
- •10- Patients with a history of drug consumption dependence or drug abuse.
- •11- Blood donation 3 months prior to baseline.
- •12- Participation in a clinical trial in the last 6 months.
- •13- To be undergone major surgery within 6 months prior to baseline.
- •14- Pregnancy and / or breastfeeding.
- •15- History or antecedents of drug allergy.
研究者
相似试验
已完成
Unknown
Bioequivalence of sustained release memeantin 21 mg capsule manufactured by Tasinm Pharmaceutical and namenda manufactured by Forest LaboratoryA crossover bioequivalence study in 24 healthy volunteers.IRCT20220209053979N13Tasnim Pharmaceutical24
招募中
不适用
Bioequivalence Study of Injectable Extended-Release Naltrexone (380 mg) of Nano Daru pharma Co. (Exopio®) and Vivitrol® (as a reference) in Iranian Healthy volunteersIRCT20130603013572N4ano Daru pharmaceutical Co.48
已完成
Unknown
Comparative bioequivalence study of the extended release tamsulosin hydrochloride 0.4 mg tablet manufactured by Tasnim CompanyBioequivalence study in healthy volunteers.IRCT20130313012810N19Tasnim pharmaceutical Company24
已完成
1 期
Bioequivalence Study of Torrent Pharmaceutical Limited's Venlafaxine Hydrochloride ER Capsules Under Fed ConditionsHealthyNCT01418612Torrent Pharmaceuticals Limited
已完成
1 期
Bioequivalence Study of Torrent Pharmaceutical Limited's Venlafaxine Hydrochloride ER Capsules Under Fed ConditionsHealthyNCT01418625Torrent Pharmaceuticals Limited